An observational study in Ovarian Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 28 open to participants now, 32 under way, none of them phase 3. Ovarian Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Among the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 15th largest by planned enrollment of the 22 observational ones that give a count, is one of 8 that started in 2025, is one of 22 observational ones, reaches primary completion later than 25 of the 31 other live ones, and was the 25th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →28 of the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–99 · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 53 across the 18 interventional studies, 160 across the 22 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
7 of the studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07546578Fondazione Policlinico Universitario Agostino Gemelli IRCCSSetting Up ctDNA Analysis on Archived Plasma Samples | 2026-11 |
| NCT07070973Fondazione Policlinico Universitario Agostino Gemelli IRCCSProactive Hemodynamic Management During Cytoreductive Surgery and HIPEC | 2026-11-30 |
| NCT05769517Fondazione Policlinico Universitario Agostino Gemelli IRCCSPrediction of Germline BRCA 1/2 Genes From Healthy Ovaries | 2026-12-31 |
| NCT07808320Fondazione Policlinico Universitario Agostino Gemelli IRCCSHERCULES: Ultrasound-Based Liver Involvement Classification in Ovarian Cancer | 2027-01 |
| NCT07645716Fondazione Policlinico Universitario Agostino Gemelli IRCCSEvaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology | 2027-01-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, patients with a PFS > 6 months could still benefit from them.
The classification of patients with recurrent disease has undergone continuous evolution over time. Essential factors to consider include patient characteristics, disease stage, and the precise genetic and molecular profile of the tumor. This study aims to evaluate survival in patients experiencing recurrence of epithelial ovarian carcinoma with an unfavorable prognosis, with the objective of improving patient categorization and management.
The study is a collection of clinical-pathological and prognostic data from patients with recurrent epithelial ovarian carcinoma with a progression-free survival of ≤ 6 months.
All patients, identified consecutively, will be registered by the investigators, after verification of the eligibility criteria.
The requested data will be recorded in a specific anonymous database. The physician will be asked to complete all the database entries that will be analyzed to evaluate the primary and secondary endpoints.
All patients with Ovarian Cancer with PFS ≤6 months meeting the inclusion criteria and whose diagnostic-therapeutic pathway took place between January 2017 and December 2023 will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed with confirmed epithelial ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma with a PFS ≤6 months.
Age \<18 years.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be trated according to standard practice
Characteristic 1 of patients
Weight (Kg) expressed as mean and standard deviation or median and interquartile range, as appropriate.
Time frame: 2 years
Characteristic 2 of patients
Height (cm) expressed as mean and standard deviation or median and interquartile range, as appropriate.
Time frame: 2 years
Characteristic 3 of patients
Age (years) expressed as mean and standard deviation or median and interquartile range, as appropriate.
Time frame: 2 years
Characteristic 4 of patients
ca 125 levels (U/mL) expressed as mean and standard deviation or median and interquartile range, as appropriate.
Time frame: 2 years
Characteristic 5 of patients
Tumor stage (1-2-3-4) expressed as absolute and percentage frequency.
Time frame: 2 years
Characteristic 6 of patients
histotype (HGSOC, LGSOC, HG endometrioid, LG endometrioid, clear cell, other) expressed as absolute and percentage frequency.
Time frame: 2 years
Characteristic 7 of patients
molecular profiling (HRD positive, HRD negative) expressed as absolute and percentage frequency.
Time frame: 2 years
Characteristic 8 of patients
mutation of BRCA ½ (mutation, wild type) expressed as absolute and percentage frequency.
Time frame: 2 years
Survival data
Progression free survival and Overall survival in months.
Time frame: 2 years
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 23 months is below that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →